Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Sexually Transmitted Diseases, Viral

ClinicalTrials.gov lists 7,371 trials for Sexually Transmitted Diseases, Viral or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 1,060.

MeSH D015229 Infections C01 C12 C23
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 1,121 Phase 1/2 Phase 1/2 220 Phase 2 Phase 2 949 Phase 2/3 Phase 2/3 90 Phase 3 Phase 3 757 Phase 4 Phase 4 619 Not applicable Not applicable 2,169 Observational Observational 1,431 Phase 1 Phase 1 1,121 Phase 1/2 Phase 1/2 220 Phase 2 Phase 2 949 Phase 2/3 Phase 2/3 90 Phase 3 Phase 3 757 Phase 4 Phase 4 619 Not applicable Not applicable 2,169 Observational Observational 1,431

Trials per phase (log scale)

1 more section with rows

24 of the 7,371 trials are tagged with Sexually Transmitted Diseases, Viral itself; the rest are tagged with a narrower condition beneath it.

Get the Sexually Transmitted Diseases, Viral report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Sexually Transmitted Diseases, Viral trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 21 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access)

Top of scale: 349

1990: 5 trials (Observational 1, Phase 3 2, Phase 2 2) 1991: 2 trials (Phase 3 1, Phase 2 1) 1992: 8 trials (Observational 5, Not applicable 1, Phase 3 2) 1993: 3 trials (Observational 1, Phase 2 2) 1994: 16 trials (Observational 7, Not applicable 3, Phase 4 2, Phase 2/3 1, Phase 1 3) 1995: 15 trials (Observational 4, Not applicable 2, Phase 3 1, Phase 2/3 1, Phase 2 4, Phase 1 3) 1996: 18 trials (Observational 7, Phase 4 1, Phase 3 3, Phase 2/3 1, Phase 2 4, Phase 1 2) 1997: 31 trials (Observational 10, Not applicable 3, Phase 3 6, Phase 2 3, Phase 1/2 3, Phase 1 6) 1998: 27 trials (Observational 9, Not applicable 3, Phase 4 2, Phase 3 3, Phase 2 5, Phase 1 5) 1999: 73 trials (Observational 12, Not applicable 9, Phase 4 6, Phase 3 13, Phase 2/3 1, Phase 2 19, Phase 1 13) 2000: 69 trials (Other 1, Observational 19, Not applicable 5, Phase 4 4, Phase 3 17, Phase 2 14, Phase 1/2 1, Phase 1 8) 2001: 88 trials (Other 1, Observational 20, Not applicable 12, Phase 4 5, Phase 3 21, Phase 2/3 3, Phase 2 18, Phase 1/2 5, Phase 1 3) 2002: 127 trials (Other 1, Observational 29, Not applicable 20, Phase 4 14, Phase 3 25, Phase 2/3 4, Phase 2 24, Phase 1/2 3, Phase 1 7) 2003: 164 trials (Other 1, Observational 31, Not applicable 26, Phase 4 22, Phase 3 26, Phase 2/3 2, Phase 2 32, Phase 1/2 7, Phase 1 17) 2004: 212 trials (Other 2, Observational 37, Not applicable 26, Phase 4 33, Phase 3 41, Phase 2/3 6, Phase 2 38, Phase 1/2 7, Phase 1 22) 2005: 261 trials (Observational 52, Not applicable 33, Phase 4 47, Phase 3 35, Phase 2/3 4, Phase 2 50, Phase 1/2 11, Phase 1 29) 2006: 258 trials (Observational 43, Not applicable 37, Phase 4 38, Phase 3 34, Phase 2/3 6, Phase 2 46, Phase 1/2 14, Phase 1 40) 2007: 289 trials (Observational 58, Not applicable 47, Phase 4 32, Phase 3 52, Phase 2/3 8, Phase 2 40, Phase 1/2 12, Phase 1 40) 2008: 294 trials (Observational 67, Not applicable 56, Phase 4 52, Phase 3 32, Phase 2/3 5, Phase 2 36, Phase 1/2 9, Phase 1 37) 2009: 349 trials (Observational 81, Not applicable 57, Phase 4 47, Phase 3 38, Phase 2/3 6, Phase 2 58, Phase 1/2 11, Phase 1 51) 2010: 266 trials (Observational 68, Not applicable 45, Phase 4 33, Phase 3 29, Phase 2/3 2, Phase 2 31, Phase 1/2 13, Phase 1 45) 2011: 229 trials (Observational 49, Not applicable 46, Phase 4 25, Phase 3 39, Phase 2/3 4, Phase 2 16, Phase 1/2 8, Phase 1 42) 2012: 187 trials (Other 1, Observational 51, Not applicable 53, Phase 4 11, Phase 3 22, Phase 2/3 4, Phase 2 20, Phase 1/2 5, Phase 1 20) 2013: 174 trials (Observational 37, Not applicable 60, Phase 4 12, Phase 3 15, Phase 2/3 4, Phase 2 15, Phase 1/2 8, Phase 1 23) 2014: 178 trials (Observational 30, Not applicable 46, Phase 4 13, Phase 3 16, Phase 2/3 3, Phase 2 22, Phase 1/2 11, Phase 1 37) 2015: 216 trials (Observational 41, Not applicable 68, Phase 4 17, Phase 3 15, Phase 2/3 1, Phase 2 26, Phase 1/2 5, Phase 1 43) 2016: 198 trials (Observational 30, Not applicable 73, Phase 4 12, Phase 3 16, Phase 2/3 7, Phase 2 18, Phase 1/2 7, Phase 1 35) 2017: 268 trials (Observational 56, Not applicable 117, Phase 4 18, Phase 3 13, Phase 2/3 1, Phase 2 17, Phase 1/2 8, Phase 1 38) 2018: 251 trials (Observational 56, Not applicable 106, Phase 4 22, Phase 3 12, Phase 2/3 2, Phase 2 14, Phase 1/2 10, Phase 1 29) 2019: 289 trials (Observational 64, Not applicable 126, Phase 4 16, Phase 3 14, Phase 2/3 1, Phase 2 22, Phase 1/2 8, Phase 1 38) 2020: 245 trials (Observational 58, Not applicable 93, Phase 4 26, Phase 3 20, Phase 2/3 2, Phase 2 18, Phase 1/2 5, Phase 1 23) 2021: 280 trials (Observational 69, Not applicable 117, Phase 4 27, Phase 3 15, Phase 2/3 2, Phase 2 22, Phase 1/2 4, Phase 1 24) 2022: 279 trials (Observational 68, Not applicable 127, Phase 4 19, Phase 3 13, Phase 2/3 3, Phase 2 16, Phase 1/2 5, Phase 1 28) 2023: 265 trials (Observational 63, Not applicable 126, Phase 4 20, Phase 3 13, Phase 2/3 1, Phase 2 17, Phase 1/2 6, Phase 1 19) 2024: 218 trials (Observational 48, Not applicable 111, Phase 4 7, Phase 3 9, Phase 2/3 2, Phase 2 13, Phase 1/2 8, Phase 1 20) 2025: 171 trials (Observational 37, Not applicable 84, Phase 4 10, Phase 3 8, Phase 2/3 2, Phase 2 11, Phase 1/2 4, Phase 1 15)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 177
2025 171
2024 218
2023 265
2022 279
2021 280
2020 245
2019 289
2018 251
2017 268

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 190 trials starting in 2026 and about 190 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 364 trials still running at the 2026-10-09 snapshot; registered median of 25 months across 4,410 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Sexually Transmitted Diseases, Viral trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 1,121
Phase 1/2 220
Phase 2 949
Phase 2/3 90
Phase 3 757
Phase 4 619
Not applicable 2,169
Observational 1,431
Expanded access 15

How many Sexually Transmitted Diseases, Viral trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 166
Recruiting 349
Enrolling by invitation 32
Active, not recruiting 201
Available 2

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Sexually Transmitted Diseases, Viral trials? (11)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Institute of Allergy and Infectious Diseases (NIAID) 1,060
ViiV Healthcare 248
Merck Sharp & Dohme LLC 140
GlaxoSmithKline 130
National Cancer Institute (NCI) 92

Showing 5 of 11 sponsors.

Start your 14-day trial Email me all 11 sponsors as a PDF

Which drugs are being tested for Sexually Transmitted Diseases, Viral? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Zidovudine 277
LAMIVUDINE 179
Efavirenz 144
Raltegravir 107
Nelfinavir 84

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Ritonavir (RTV) low 164
didanosine, ddI (drug) 120
Stavudine 113
Nevirapine IR 109
Dolutegravir Pill 95

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Sexually Transmitted Diseases, Viral trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 1,394 230
Any Event in SOC 823 16
Gastroenteritis 791 151
Road traffic accident 743 51
Appendicitis 722 152

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Sexually Transmitted Diseases, Viral? (55)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. JAMA network open 2020 Yes
Persistence and clinical relevance of Zika virus in the male genital tract. Nature reviews. Urology 2019 Yes
Mathematical modeling of HIV-1 transmission risk from condomless anal intercourse in HIV-infected MSM by the type of initial ART. PloS one 2019 Yes
Low awareness and use of pre-exposure prophylaxis among adolescents and young adults in high HIV and sexual violence prevalence settings. Medicine 2019 Yes
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study. The lancet. HIV 2018 Yes

Showing 5 of 55 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Sub-conditions in MeSH (4)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages